The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis

European Journal of Pharmacology

Volumn 615, Issue 1-3, 2009, Pages 228-233

  Donia, Marco ^a   Mijatovic, Sanja ^b   Maksimovic Ivanic, Danijela ^b   Miljkovic, Djordje ^b   Mangano, Katia ^a   Tumino, Salvatore ^a   Biondi, Antonio ^a   Basile, Francesco ^a   Al Abed, Yousef ^c   Stosic Grujicic, Stanislava ^b   Nicoletti, Ferdinando ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c N Shore Univ Hosp Cornell Med C   (United States)

Author keywords

Cancer; GIT 27NO; Hepatitis; Nitric oxide; Nitric oxide donors; Prostate cancer

Indexed keywords

3 PHENYL 4,5 DIHYDRO 5 ISOXAZOLE ACETIC ACID NITRIC OXIDE; ACETYLSALICYLIC ACID; AMINOTRANSFERASE; ANDROGEN; ANTINEOPLASTIC AGENT; CISPLATIN; CONCANAVALIN A; NITRIC OXIDE DONOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL STRAIN LNCAP; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HEPATITIS; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT;

ACETIC ACIDS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CONCANAVALIN A; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; MALE; MICE; MICE, INBRED STRAINS; MICE, NUDE; NEOPLASM TRANSPLANTATION; NITRIC OXIDE DONORS; OXAZOLES; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 67549086078     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.04.069     Document Type: Article

References (31)

1. Adams C., McCarthy H.O., Coulter J.A., Worthington J., Murphy C., Robson T., and Hirst D.G. Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells. J. Gene Med. 11 2 (2008) 160-168
2. Bézière N., Goossens L., Pommery J., Vezin H., Touati N., Hénichart J.P., and Pommery N. New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines. Bioorg. Med. Chem. Lett. 18 16 (2008) 4655-4657
3. Bohlinger I., Leist M., Barsig J., Uhlig S., Tiegs G., and Wendel A. Interleukin-1 and nitric oxide protect against tumor necrosis factor alpha-induced liver injury through distinct pathways. Hepatology 22 (1995) 1829-1837
4. de Wit R. Chemotherapy in hormone-refractory prostate cancer. BJU Int. 101 (2008) 11-15
5. Di Marco R., Xiang M., Zaccone P., Leopardi C., Franco S., Meroni P., and Nicoletti F. Concanavalin A-induced hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. Autoimmunity 31 (1999) 75-83
6. Ding J.W., Wang K., Brems J.J., and Gamelli R.L. Protection against concanavalin A-induced hepatocyte apoptosis by molsidomine is time-dependent. J. Am. Coll. Surg. 198 (2004) 67-77
7. Fiorucci S., Santucci L., Antonelli E., Distrutti E., Del Sero G., Morelli O., Romani L., Federici B., Del Soldato P., and Morelli A. NO-aspirin protects from T cell-mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines. Gastroenterology 118 (2000) 404-421
8. Fizazi K., and Navone N.M. Preclinical models of prostate cancer. Bull. Cancer 92 (2005) 129-141
9. Harhaji L.J., Mijatović S., Maksimović-Ivanić D., Stojanović I., Momcilović M., Maksimović V., Tufegdzić S., Marjanović Z., Mostarica-Stojković M., Vucinić Z., and Stosić-Grujicić S. Anti-tumor effect of Coriolus versicolor methanol extract against mouse B16 melanoma cells: In vitro and in vivo study. Food Chem. Toxicol. 46 (2008) 1825-1833
10. Hasselblatt P., Rath M., Komnenovic V., Zatloukal K., and Wagner E.F. Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 23 (2007) 1105-1110
11. Huerta-Yepez S., Vega M., Escoto-Chavez S.E., Murdock B., Sakai T., Baritaki S., and Bonavida B. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide 20 (2009) 39-52
12. Kashfi K., Ryan Y., Qiao L.L., Williams J.L., Chen J., Del Soldato P., Traganos F., and Rigas B. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J. Pharmacol. Exp. Ther. 303 3 (2002) 1273-1282
13. Klotz L. Maximal androgen blockade for advanced prostate cancer. Best Pract. Res. Clin. Endocrinol. Metab. 22 (2008) 331-340
14. Laskin J.D., Heck D.E., Gardner C.R., and Laskin D.L. Prooxidant and antioxidant functions of nitric oxide in liver toxicity. Antioxid. Redox Signal 3 (2001) 261-271
15. Lattouf J.B., and Saad F. Preservation of bone health in prostate cancer. Curr. Opin. Support Palliat. Care 1 (2007) 192-197
16. Maksimovic-Ivanic D., Mijatovic S., Harhaji L., Miljkovic D., Dabideen D., Fan Cheng K., Mangano K., Malaponte G., Al-Abed Y., Libra M., Garotta G., Nicoletti F., and Stosic-Grujicic S. Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo.Mol. Cancer. Ther. 7 (2008) 510-520
17. Mijatovic S., Maksimovic-Ivanic D., Mojic M., Malaponte G., Libra M., Cardile V., Miljkovic D., Harhaji L., Dabideen D., Cheng K.F., Bevelacqua Y., Donia M., Garotta G., Al-Abed Y., Stosic-Grujicic S., and Nicoletti F. Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. Nitric Oxide 19 (2008) 177-183
18. Mijatovic S., Maksimovic-Ivanic D., Radovic J., Miljkovic D., Kaludjerovic G.N., Sabo T.J., and Trajkovic V. Aloe emodin decreases the ERK-dependent anticancer activity of cisplatin. Cell. Mol. Life Sci. 62 (2005) 1275-1282
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
20. Nicoletti F., Beltrami B., Raschi E., Di Marco R., Magro G., Grasso S., Bendtzen K., Fiorelli G., and Meroni P.L. Protection from concanavalin A (Con A)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate. Clin. Exp. Immunol. 110 (1997) 479-484
21. Nicoletti F., Di Marco R., Zaccone P., Selvaggio A., Magro G., Bendtzen K., and Meroni P. Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody and exacerbated by exogenous IL-12 through an interferon-gamma-dependent mechanism. Hepatology 32 (2000) 728-733
22. Nicoletti F., Zaccone P., Xiang M., Magro G., Di Mauro M., Di Marco R., Garotta G., and Meroni P. Essential pathogenetic role for interferon (IFN-)gamma in concanavalin A-induced T cell-dependent hepatitis: exacerbation by exogenous IFN-gamma and prevention by IFN-gamma receptor-immunoglobulin fusion protein. Cytokine 12 (2000) 315-323
23. Rigas B. Novel agents for cancer prevention based on nitric oxide. Biochem. Soc. Trans. 35 (2007) 1364-1368
24. Rigas B., and Williams J.L. NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide 19 (2008) 199-204
25. Rubin M.A. Targeted therapy of cancer: new roles for pathologists-prostate cancer. Mod. Pathol. 21 (2008) 44-55
26. Schostak M., Miller K., and Schrader M. Radical prostatectomy in the 21st century - the gold standard for localized and locally advanced prostate cancer. Front. Radiat. Ther. Oncol. 41 (2008) 7-14
27. Sharkey J., Cantor A., Solc Z., Huff W., Chovnick S.D., Behar R.J., Perez R., Otheguy J., and Rabinowitz R. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. Brachytherapy 4 (2005) 34-44
28. Stewart G.D., Nanda J., Brown D.J., Riddick A.C., Ross J.A., and Habib F.K. NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int. J. Cancer 124 (2009) 223-232
29. Stojanovic I., Cuzzocrea S., Mangano K., Mazzon E., Miljkovic D., Wang M., Donia M., Al Abed Y., Kim J., Nicoletti F., Stosic-Grujicic S., and Claesson M. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin. Immunol. 123 (2007) 311-323
30. Tiegs G., Hentschel J., and Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Invest. 90 (1992) 196-203
31. van Weerden W.M., Bangma C., and de Wit R. Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. Br. J. Cancer 13 (2009) 13-18